{"title":"慢性心力衰竭的β -肾上腺素能阻断。","authors":"M Bristow, J D Port","doi":"10.1080/140174398428045","DOIUrl":null,"url":null,"abstract":"<p><p>In summary, beta-blockade is currently the most promising \"new\" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.</p>","PeriodicalId":79533,"journal":{"name":"Scandinavian cardiovascular journal. Supplement","volume":"47 ","pages":"45-55"},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/140174398428045","citationCount":"40","resultStr":"{\"title\":\"Beta-adrenergic blockade in chronic heart failure.\",\"authors\":\"M Bristow, J D Port\",\"doi\":\"10.1080/140174398428045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In summary, beta-blockade is currently the most promising \\\"new\\\" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.</p>\",\"PeriodicalId\":79533,\"journal\":{\"name\":\"Scandinavian cardiovascular journal. Supplement\",\"volume\":\"47 \",\"pages\":\"45-55\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/140174398428045\",\"citationCount\":\"40\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian cardiovascular journal. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/140174398428045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian cardiovascular journal. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/140174398428045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Beta-adrenergic blockade in chronic heart failure.
In summary, beta-blockade is currently the most promising "new" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
